United StatesHealth

Merck & Co. (NYSE: MRK), known as MSD outside the U.S. and Canada, announced a significant restructuring of its Human Health division on Monday, February 23, 2026.

GeneDx Holdings (NASDAQ:WGS) reported fourth-quarter 2025 results on Monday that underscored its successful pivot to a high-margin, "genomic-first" business model.

Gilead Sciences (NASDAQ:GILD) announced Monday it has entered into a definitive agreement to acquire Arcellx (NASDAQ:ACLX), moving to take full control of a high-potential cell therapy pipeline for multiple myeloma.

Novo Nordisk (NYSE:NVO) shares tumbled Monday morning after the Danish drugmaker announced that its highly anticipated obesity treatment, CagriSema, failed to achieve non-inferiority against Eli Lilly’s (NYSE:LLY) blockbuster tirzepatide in a head-to-head Phase 3 trial.

AstraZeneca (NASDAQ:AZN) announced on Friday that the U.S. Food and Drug Administration (FDA) has approved its BTK inhibitor, Calquence (acalabrutinib), in combination with venetoclax as the first all-oral, fixed-duration treatment for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

National Healthcare Properties (NASDAQ:NHPAP), the New York-based REIT focused on senior housing and outpatient medical facilities, reported a massive surge in profitability for 2025 as it reaps the rewards of its management internalization and portfolio optimization.

MediciNova (NASDAQ:MNOV), the La Jolla-based biopharmaceutical firm, released its fourth-quarter and full-year 2025 financial results on Friday, February 20, 2026.

AMN Healthcare Services (NYSE:AMN), the nation’s largest healthcare staffing firm, saw its shares jump on Thursday after providing a blockbuster revenue outlook for the first quarter of 2026.

AbbVie (NYSE:ABBV) announced on February 20, 2026, that the U.S. Food and Drug Administration (FDA), has approved the combination of VENCLEXTA (venetoclax) and acalabrutinib for adult patients with previously untreated chronic lymphocytic leukemia (CLL).

Madrigal Pharmaceuticals (NASDAQ:MDGL), the West Conshohocken, Pennsylvania-based leader in liver disease therapies, reported fourth-quarter revenue that outpaced Wall Street estimates, driven by the explosive commercial trajectory of its flagship MASH treatment, Rezdiffra.

Plano, Texas-based Integer Holdings (NYSE:ITGR), a leading outsource manufacturer of medical devices and components, reported fourth-quarter net income of $48.6 million, or $1.38 per share, for the period ended December 2025.

Hims & Hers Health (NYSE:HIMS), the San Francisco-based telehealth leader, announced a definitive agreement on Thursday to acquire Eucalyptus, an Australian digital health powerhouse, in a deal valued at up to $1.15 billion.